LIVERPOOL, England — Two authors of the 2016 OARSI White Paper outlined key data that led to the FDA’s acceptance of osteoarthritis as a serious disease and laid out future challenges for clinicians managing the disease during the OARSI World Congress on Osteoarthritis.

Gillian Hawker, MD, MSc , chair of the department of medicine and Sir John and Lady Eaton Professor of Medicine at the University of Toronto, and Nigel Arden, MD, MSc, professor in rheumatic diseases and consultant rheumatologist at the University of Southampton in the U.K., zeroed in on topics associated with epidemiology, morbidity and mortality of OA.